Kefah Mokbel, Chair of Breast Cancer Surgery at London Breast Institute and Honorary Professor of Medicine at Cardiff University School of Medicine, shared a post on LinkedIn:
“ctDNA (liquid biopsy) is a better prognostic indicator than pCR in the context of neoadjuvant systemic therapy for breast cancer.
This study highlights the prognostic value of ctDNA after NAT, showing that ctDNA negativity captures the absence of systemic disease potential more effectively than pCR, which reflects local disease eradication. However, the modest NPV for residual disease, together with ongoing challenges of standardization, robustness, and reproducibility of ctDNA assays, underscores the need for larger, validated studies before clinical adoption.”
More posts featuring Kefah Mokbel.